Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to
treat. For patients with advanced and metastatic disease, chemotherapy has yielded only …

Abstract Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal
adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC …

Background: Bortezomib is a novel, first-in-class peptide which reversibly inhibits the
proteasome and is Food and Drug Administration approved for the treatment of multiple …

Large granular lymphocyte (LGL) leukemia features a group of indolent lymphoproliferative
diseases that display a strong association with various autoimmune conditions …

Richter transformation in chronic lymphocytic leukaemia (CLL) represents an entity of
considerable genetic, molecular, immunological and clinical heterogeneity. A rare …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For
most patients, there are no options for targeted therapy, and existing treatments are limited …

Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer
therapies. Targeting tumors with kinase inhibitors induces complex adaptive programs that …

Patient-derived organoid models are proving to be a powerful platform for both basic and
translational studies. Here we conduct a methodical analysis of pancreatic ductal …

Purpose: The tumor microenvironment plays a key role in cancer development and
progression and is involved in resistance to chemo-and immunotherapy. Cancer-associated …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is largely unresponsive to checkpoint
inhibitors. Blockade of the CXCR4/CXCL12 axis increases intratumoral trafficking of …